|

Extended Ablation Versus Pulmonary Vein Isolation to Treat Persistent Atrial Fibrillation

RECRUITINGN/ASponsored by Charles University, Czech Republic
Actively Recruiting
PhaseN/A
SponsorCharles University, Czech Republic
Started2026-06-01
Est. completion2029-12-31
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted

Summary

The aim is to determine the effect of extended ablation (pre-specified linear PF/RF lesion set) in addition to PVI in symptomatic persistent AF patients on AF/AT/AFL recurrence. The study is designed as multicenter, randomized trial. Eligible patients are patients with persistent AF (but not long-standing persistent AF) planned for a first-ever AF ablation procedure. Patients will be randomly assigned 1:1 either to: i) PVI-only, or ii) PVI-plus arms. Patients in both groups will undergo catheter ablation using an ablation system capable of performing PF and RF ablation (Sphere-9, Affera, Medtronic). Patients randomized to the PVI-only arm will undergo only PVI. Patients randomized to the PVI-plus arm will undergo PVI plus linear lesions (roof, bottom line, lateral or anterior MI line, and septal line in the LA; intercaval line and cavotricuspid line in the RA). The primary endpoint will be freedom from recurrent AF/AT/AFL, assessed as time-to-first recurrence in the period of 12 months after randomization (post 2-month blanking period). Secondary clinical endpoints will be 1) 1) AF/AT/AFL burden during the first 12 months after randomization, 2) 2) Quality of life according to the AFEQT questionnaire score at 12 months, 3) 3) AF/AFL/AT-related outcomes (hospitalization or emergency visits), 4) MACE defined as cardiovascular death, stroke, myocardial infarction, or hospitalization for heart failuree, 5) A composite of pre-specified, procedure-related SAE within 7 days after the procedure, including clinically relevant delayed SAEs adjudicated as related to the index ablation procedure. Secondary endpoints will be evaluated throughout the entire (minimum 12-month) follow-up period.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* symptomatic persistent AF
* ≥1 episode of persistent AF in the last 12 months
* signed informed consent

Exclusion Criteria:

* first-manifested AF, paroxysmal AF, long-standing persistent AF, permanent AF
* SR on admission without Class I/III AADs
* AF of secondary cause (e.g. hyperthyroidism)
* any previous LA ablation
* severe valvular disease (mitral valve insufficiency ≥3+, moderate or severe aortic stenosis) or history of valvular surgery or intervention
* left ventricular ejection fraction ≤40%
* pulmonary hypertension (estimated systolic pulmonary artery pressure ≥40 mm Hg)
* symptomatic coronary artery disease
* pregnancy
* LA anteroposterior diameter ≥55 mm
* body mass index ≥40 kg/m2
* age ≥80 years
* chronic kidney disease stage 3b or higher
* contraindication to anticoagulation
* general contraindications of catheter ablation
* life expectancy \<2 years due to other comorbidities

Conditions2

Atrial Fibrillation (AF)Heart Disease

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.